EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus

Ruxue Zhang iD, Xiaoqin Jian, Yumin Zhang, Yuan Sun iD, Mengwei Xu, Junyuan Cao, Guanghui Tian, Li Xiang iD, Jiangshan Shen iD, Gengfu Xiao, Tianwen Hu, Leike Zhang iD

Journal of Virology · 19.05.2026 · 100 (5)

DOI: 10.1128/jvi.00006-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 19.05.2026. Verfasst von Ruxue Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Center for Biosafety Mega-Science, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Influenza A virus, Coinfection. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) and influenza virus are the principal contributors to respiratory tract infections worldwide. Clinical treatment of RSV or influenza A virus (IAV) is limited and may be postponed because of misdiagnosis or coinfection with multiple pathogens. Here, we described VV251, the prodrug of 4′-fluorouridine, a novel oral nucleoside analog that exhibits potent inhibitory activity against RSV laboratory strains and clinical isolates, as well as IAV, in vitro . The EC 50 values of VV251 against these viruses ranged from nanomolar to low micromolar. Moreover, VV251 significantly reduced the viral titer of RSV A2 or IAV PR8 in a BALB/c infection model. Importantly, we further established a simultaneous RSV/IAV coinfection model to investigate the antiviral activity of VV251. Oral administration of VV251 once daily significantly inhibited viral replication and decreased the mortality of RSV/IAV-coinfected mice. Our findings establish VV251 as a broad-spectrum drug candidate for the treatment of RSV, IAV, and RSV/IAV coinfection. IMPORTANCE Respiratory syncytial virus (RSV) and influenza virus are the two predominant causative agents of acute respiratory tract infections, leading to a substantial number of hospitalizations and thousands of deaths annually. The cost of treating disease caused by infection with RSV and influenza viruses is a huge financial burden on the world. We have identified a nucleotide analog with favorable pharmacokinetic properties and antiviral activity against RSV and influenza A virus (IAV) during mono- or coinfection in a mouse model. This compound has the potential to be used for the treatment of RSV, IAV, and RAV/IAV coinfection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntiviral AgentsInfluenza A virusCoinfectionOrthomyxoviridae InfectionsUridineAnimalsMiceMice, Inbred BALB CHumansAdministration, OralDogsVirus ReplicationFemaleRespiratory Syncytial VirusesDisease Models, AnimalMadin Darby Canine Kidney CellsDeoxycytidine

Stichwörter der Autor:innen

VV251coinfection treatmentinfluenza A virusrespiratory syncytial virus

Substanzen

Antiviral AgentsUridine4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidineDeoxycytidine

Autor:innen und Institutionen

  • State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Center for Biosafety Mega-Science, Wuhan, Hubei, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Hubei Jiangxia Laboratory, Wuhan, Hubei, China.
  • Vigonvita Shanghai Co., Ltd., Shanghai, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China.

ORCID-Profile: Ruxue Zhang, Yuan Sun, Li Xiang, Jiangshan Shen, Leike Zhang

Zitieren

APA

Zhang, R., Jian, X., Zhang, Y., Sun, Y., Xu, M., Cao, J., Tian, G., Xiang, L., Shen, J., Xiao, G., Hu, T., & Zhang, L. (2026). The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus. Journal of Virology, 100(5). https://doi.org/10.1128/jvi.00006-26

Vancouver

Zhang R, Jian X, Zhang Y, Sun Y, Xu M, Cao J, et al. The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus. Journal of Virology. 2026;100(5). doi:10.1128/jvi.00006-26

BibTeX
@article{Zhang2026,
  author = {Zhang, Ruxue and Jian, Xiaoqin and Zhang, Yumin and Sun, Yuan and Xu, Mengwei and Cao, Junyuan and Tian, Guanghui and Xiang, Li and Shen, Jiangshan and Xiao, Gengfu and Hu, Tianwen and Zhang, Leike},
  title = {The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {5},
  doi = {10.1128/jvi.00006-26}
}
Kostenlos starten →